COVID-19/SARS-COV-2 / RESEARCH PAPER
Right ventricular dysfunction and pulmonary hypertension in COVID-19: a meta-analysis of prevalence and its association with clinical outcome
| 1 | Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga - Dr. Soetomo General Hospital, Surabaya, Indonesia, Indonesia |
| 2 | Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia, Indonesia |
CORRESPONDING AUTHOR
Yudi Her Oktaviono
Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga - Dr. Soetomo General Hospital, Surabaya, Indonesia, Surabaya, Indonesia
Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga - Dr. Soetomo General Hospital, Surabaya, Indonesia, Surabaya, Indonesia
Submission date: 2021-01-26
Final revision date: 2021-04-27
Acceptance date: 2021-05-03
Online publication date: 2021-05-05
KEYWORDS
TOPICS
CardiologyFamily MedicineInfectious DiseasesInternal Medicine and GeriatricsMicrobiology and VirologyHeart failureCardiomyopathyIntensive Care MedicinePulmonologyThrombosis and HemostasisVascular ImagingEchocardiography
ABSTRACT
Introduction:
Rapid spread of COVID-19 has caused detrimental effect globally. Involvement of ACE2 receptor has identified COVID-19 as a multi-organ disease. Preliminary studies have provided evidence that cardiac involvement, including right ventricular dysfunction (RVD) and pulmonary hypertension (PH) were found in COVID-19 cases, even in the non-advanced stage. This meta-analysis aims to analyze the prevalence of RVD and PH, and its association with COVID-19 clinical outcome.
Material and methods:
A systematic data search was conducted through PubMed, MedRxiv, ProQuest, Science Direct, and Scopus databases using constructed keywords based on MeSH terms. Any outcomes regarding mortality, severity, ICU admission, and mechanical ventilation usage were analyzed using Revman v.5.4 and Stata v.16.
Results:
A total of 16 eligible studies (1,728 patients) were included. Pooled prevalence of RVD in COVID-19 was 19% (95%CI: 13%−25%), and PH was 22% (95% CI: 14%-31%). RVD was associated with increased mortality (OR=2.98 [95%CI: 1.50-5.89], p=0.002), severity (OR= 3.61 [95%CI: 2.05−6.35], p<0.001), ICU admission (OR= 1.70 [95%CI: 1.12−2.56], p=0.01), and mechanical ventilation (MV) usage (OR= 1.60 [95%CI: 1.14−2.25], p=0.007). PH was also associated with increased mortality (OR=5.42 [95%CI: 2.66-11.06], p<0.001), severity (OR=5.74 [95%CI: 2.28-14.49], p<0.001), and ICU admission (OR: 12.83 [95% CI: 3.55-46.41], p<0.001).
Conclusions:
RVD and PH were prevalent in COVID-19 and associated with mortality, severity, ICU admission, and MV usage in COVID-19 patients. Bedside echocardiography examination could be considered as a novel risk stratification tool in COVID-19.
Rapid spread of COVID-19 has caused detrimental effect globally. Involvement of ACE2 receptor has identified COVID-19 as a multi-organ disease. Preliminary studies have provided evidence that cardiac involvement, including right ventricular dysfunction (RVD) and pulmonary hypertension (PH) were found in COVID-19 cases, even in the non-advanced stage. This meta-analysis aims to analyze the prevalence of RVD and PH, and its association with COVID-19 clinical outcome.
Material and methods:
A systematic data search was conducted through PubMed, MedRxiv, ProQuest, Science Direct, and Scopus databases using constructed keywords based on MeSH terms. Any outcomes regarding mortality, severity, ICU admission, and mechanical ventilation usage were analyzed using Revman v.5.4 and Stata v.16.
Results:
A total of 16 eligible studies (1,728 patients) were included. Pooled prevalence of RVD in COVID-19 was 19% (95%CI: 13%−25%), and PH was 22% (95% CI: 14%-31%). RVD was associated with increased mortality (OR=2.98 [95%CI: 1.50-5.89], p=0.002), severity (OR= 3.61 [95%CI: 2.05−6.35], p<0.001), ICU admission (OR= 1.70 [95%CI: 1.12−2.56], p=0.01), and mechanical ventilation (MV) usage (OR= 1.60 [95%CI: 1.14−2.25], p=0.007). PH was also associated with increased mortality (OR=5.42 [95%CI: 2.66-11.06], p<0.001), severity (OR=5.74 [95%CI: 2.28-14.49], p<0.001), and ICU admission (OR: 12.83 [95% CI: 3.55-46.41], p<0.001).
Conclusions:
RVD and PH were prevalent in COVID-19 and associated with mortality, severity, ICU admission, and MV usage in COVID-19 patients. Bedside echocardiography examination could be considered as a novel risk stratification tool in COVID-19.
RELATED ARTICLE
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.